NEO:CYBN
NEO:CYBN

We are a leading Life Sciences Company
focused on psychedelic drug development,
unique delivery mechanisms, improved novel
compounds and protocols that target
psychiatric and neurological conditions.

IP STRATEGY

Covering chemically synthesized compounds, delivery mechanisms,
screeners & protocols and new drug formulations.

FULLY APPROVED PSILOCYBIN

Cybin aims to become one of the first life sciences companies to
launch a fully approved psilocybin product targeting depression.(2)(3)

SERIES-A ROUND

Approx $10M successfully raised thus far from Seed and Series-A round.

STRATEGIC SHAREHOLDERS

Strategic shareholder base with long term investment thesis including
biotech funds and former heads of top fortune 100 CPG companies.

MEDICAL TEAM

Has run multiple clinical trials and facilitated over C$1B in pharma sales.

M&A STRATEGY

To attain intellectual property, capabilities and revenue that
strategically align with the business(2)

“With 1 in 4 people affected by mental or neurological disorders, our aim is to become the first life sciences company to bring a psilocybin drug to market targeting Major Depressive Disorder (MDD).”

OPERATING DIVISIONS

Wholly-owned subsidiary of Cybin corp.

SERENITY LIFE SCIENCE INC.

Big pharma has had a 10+ year stalemate on any
new drug innovations surrounding mental illness.
We believe the next 10 years of newly discoverable
data from psychedelic studies can potentially
createan entirely new marketplace of safe and
effective drugs derived from psychedelics.
CLINICAL TRIALS

Wholly-owned subsidiary of cybin corp.

CLINICAL TRIAL:

PHASE 2

A Phase 2, Randomized, Parallel Group, Bioequivalence (BE) Study of Psilocybin 1 mg, 3 mg, 5 mg and 7 mg administered with sublingual film to 25 mg Oral Capsule Followed by Placebo-Controlled Safety and Efficacy Trial with Selected Dose in Patients with  Major Depressive Disorder (MDD).